Validation of the International Study Group of Rectal Cancer definition and severity grading of anastomotic leakage.
Yakup Kulu, Alexis Ulrich, Thomas Bruckner...
https://pubmed.ncbi.nlm.nih.gov/23623834/Actively Recruiting
Led by Tongji Hospital · Updated on 2026-05-26
72
Participants Needed
3
Research Sites
152 weeks
Total Duration
Researchers are studying adults with low or mid rectal cancer who are scheduled for ultra-low anterior resection surgery. The study aims to find out if using somatostatin combined with a clear liquid diet after surgery can prevent severe leakage where the bowel is joined, and how this compares to the standard use of a prophylactic diverting stoma. The trial also evaluates medical problems, bowel function, recovery, and quality of life during follow-up. Participants will be randomly assigned to one of two groups one will receive somatostatin by intravenous infusion every 12 hours for 7 days plus a clear liquid diet after surgery without a diverting stoma, while the other group will have a prophylactic diverting stoma created during surgery and receive standard care without routine somatostatin. Both groups will get usual perioperative management at the participating centers. During the study, participants will be monitored for severe anastomotic leakage within one month of surgery, along with other postoperative complications, bowel function, quality of recovery, and quality of life. Follow-up assessments will continue for up to 3 years after surgery to review longer-term outcomes and recovery.
CONDITIONS
Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection
A
Antian Lu
S
Senyan Lai
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tongji Hospital
Lead Sponsor
Ezhou Central Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Day of surgery
Participants undergo ultra-low anterior resection surgery. Depending on their assigned group, they will either receive a prophylactic diverting stoma or no stoma.
1 visit (in-person)
Duration - 7 days after surgery
Participants in the experimental group receive somatostatin infusion plus a clear liquid diet for 7 days after surgery. Participants in the control group receive standard postoperative care with a prophylactic diverting stoma.
Daily visits or assessments during the 7-day treatment period
Duration - Up to 1 month after surgery
Participants are monitored for postoperative complications, bowel function, and quality of recovery up to 1 month after surgery.
Visits at 7 days, 14 days, and 1 month after surgery
Duration - Up to 3 years after surgery
Participants are followed for longer-term functional outcomes and quality of life for up to 3 years after surgery.
Periodic visits during follow-up as per clinical practice
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yakup Kulu, Alexis Ulrich, Thomas Bruckner...
https://pubmed.ncbi.nlm.nih.gov/23623834/Celeste Y Kang, Wissam J Halabi, Obaid O Chaudhry...
https://pubmed.ncbi.nlm.nih.gov/22986932/Nuh N Rahbari, Jürgen Weitz, Werner Hohenberger...
https://pubmed.ncbi.nlm.nih.gov/20004450/Peter A Stark, Paul S Myles, Justin A Burke
https://pubmed.ncbi.nlm.nih.gov/23411725/Katrine J Emmertsen, Søren Laurberg
https://pubmed.ncbi.nlm.nih.gov/22504191/Philip Stevens, Rhiannon E Foulkes, Jake S Hartford-Beynon...
https://pubmed.ncbi.nlm.nih.gov/21814141/Peter Matthiessen, Olof Hallböök, Jörgen Rutegård...
https://pubmed.ncbi.nlm.nih.gov/17667498/Tongji Hospital
Lead Sponsor
Ezhou Central Hospital
Collaborating Sponsor